Publications in collaboration with researchers from Hospital POVISA (15)

2022

  1. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group

    Cancer Treatment and Research Communications, Vol. 33

2021

  1. Do clinical trials meet current care needs? Views of digestive oncology specialists in galicia (spain) using the delphi method

    Healthcare (Switzerland), Vol. 9, Núm. 6

  2. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  3. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

    ESMO open, Vol. 6, Núm. 2, pp. 100090

2020

  1. First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study

    Journal of Geriatric Oncology, Vol. 11, Núm. 8, pp. 1263-1267

  2. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13

2019

  1. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258

  2. Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

    Annals of Oncology, Vol. 30, pp. iv42-iv43

2018

  1. Real world data of nivolumab for previously treated non-small cell lung cancer patients: A Galician lung cancer group clinical experience

    Translational Lung Cancer Research, Vol. 7, Núm. 3, pp. 404-415

2016

  1. EGFR testing and clinical management of advanced NSCLC: A galician lung cancer group study (GGCP 048-10)

    Cancer Management and Research, Vol. 8, pp. 11-20

  2. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia)

    Oncology Letters, Vol. 12, Núm. 2, pp. 1403-1407

2014

  1. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 3, pp. 451-457

  2. Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: Review of patient profile

    Anti-Cancer Drugs, Vol. 25, Núm. 4, pp. 368-374

2012

  1. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

    Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 10, pp. 1389-1396

2007

  1. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: A lung cancer Galician group phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 60, Núm. 5, pp. 725-732